<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03756766</url>
  </required_header>
  <id_info>
    <org_study_id>OVG 2017/02</org_study_id>
    <nct_id>NCT03756766</nct_id>
  </id_info>
  <brief_title>Understanding RSV: Severe Disease and the Long Term Consequences</brief_title>
  <official_title>REspiratory Syncytial Virus Consortium in EUrope (RESCEU):Presumed Risk Factors and Biomarkers for RSV-related Severe Disease and Related Sequelae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Respiratory syncytial virus consortium in Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a case-control, sample based study. 275 cases (Group 1), infants &lt;12&#xD;
      months old with RSV infection and 40 controls (Group 2), otherwise healthy infants &lt;12 months&#xD;
      old without RSV infection will be recruited. Samples will be taken on enrolment and for&#xD;
      infants in Group 1; repeated at 7 weeks convalescence. There will be annual follow up by&#xD;
      questionnaire for up to 6 years and a minimum of 1 year, depending at what stage in the study&#xD;
      the infant is enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human respiratory syncytial virus (RSV) causes severe disease in the very young, elderly and&#xD;
      in high risk groups. Worldwide in 2005 there were an estimated 34 million cases of acute&#xD;
      lower respiratory tract infection (ALRI), 3.4 million ALRI hospitalisations and 55,000 to&#xD;
      199,000 deaths associated with RSV in children &lt;5 years old. RSV infection in childhood is&#xD;
      associated with subsequent wheezing and asthma. These long-term sequelae pose a substantial&#xD;
      additional burden on healthcare systems. There is a parallel need to assemble clinical&#xD;
      resources to identify the correlates of severe RSV disease for clinical management,&#xD;
      classification of disease severity in clinical trials and identification of biomarkers for&#xD;
      severe disease, which are currently lacking.&#xD;
&#xD;
      Group 1: Infants under 12 months with an RSV infection will have nasopharyngeal swabs, blood,&#xD;
      urine and stool samples taken at the onset of infection and again 6 - 8 weeks later, in&#xD;
      convalescence. An online diary will be completed for 2 weeks during illness to record the&#xD;
      participant and parent health. The participant and their family will be followed up annually&#xD;
      by questionnaire, for a maximum of 6 years. When the study data are analysed, the infants&#xD;
      will be subdivided into 4 further groups; healthy infants requiring hospitalisation, healthy&#xD;
      infants not requiring hospitalisation, infants with co-morbidity, requiring hospitalisation&#xD;
      and infants with a co-morbidity not requiring hospitalisation. Group 2: Well, healthy&#xD;
      infants, under 12 months with no acute respiratory infection will have nasopharyngeal&#xD;
      swab,blood, urine and stool samples taken on enrolment. They will receive a follow up contact&#xD;
      7 days after enrolment to assess if they have developed any illness. The participant and&#xD;
      their family will be followed up annually by questionnaire, for a maximum of 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ribonucleic acid (RNA) transcripts (Transcriptomics) that are up and down regulated in severe RSV infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Analysis of blood to determine cellular expression of RNA during a severe, acute RSV respiratory tract infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular protein concentration changes (proteomics) in response to severe RSV infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Analysis of blood samples to determine how cellular protein concentrations change in response to severe RSV infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular metabolite concentration changes associated with severe RSV disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Analysis of urine and blood to identify which metabolic pathways are up-regulated at a cellular level following severe RSV infection. This is determined by measuring metabolic by-products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relationship between infant RSV infection of different severity and school age asthma</measure>
    <time_frame>Year 6</time_frame>
    <description>Symptoms of asthma, diagnosis and use of asthma medication will be measured by parental questionnaire/medical records.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ribonucleic acid (RNA) transcripts that are up or down regulated and contribute to respiratory sequelae following RSV infection in infants</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of blood samples will determine changes in cellular RNA associated with RSV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular protein concentration changes (Proteomics) affecting respiratory sequelae following RSV infection in infants</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of blood to determine how cellular protein production is up or down regulated in response to RSV infection to correlate with subsequent respiratory sequelae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular metabolite concentration changes that contribute to respiratory sequelae following RSV infection</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of blood and urine to determine which cellular metabolites are produced in increasing quantities during RSV infection and which are subsequently responsible for respiratory sequelae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory sequelae following RSV infection in infants</measure>
    <time_frame>3 years</time_frame>
    <description>Respiratory sequelae in participants will be determined by completion of a baseline questionnaire followed by an annual questionnaire for a maximum of 3 years.&#xD;
The questionnaires record patient demographics, number of siblings, family history of atopy, exposure to household smoke and pets and the ability of the child and family members to complete their usual activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load associated with mild and severe RSV disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Nasopharyngeal swabs will be taken at baseline and at 6-8weeks to measure viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic sequence of RSV associated with mild and severe disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Nasopharyngeal samples will be taken at baseline and at 6-8weeks do determine the genetic sequencing of the Respiratory Syncytial Virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response during RSV infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whole blood will be used for flow cytometric cell phenotyping to determine which immune cells are activated in response to RSV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release associated with severe RSV disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whole blood will be used to perform intracellular cytokine staining in response to RSV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Altered gene expression associated with severe RSV disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood sampling to determine epigenetic changes associated with RSV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV disease severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>This is determined using a standardized respiratory clinical severity score (ReSVinet) which is performed at baseline.&#xD;
This score has 7 subscales;&#xD;
Feeding intolerance (Score 0-3)&#xD;
Medical intervention (score 0-3)&#xD;
Respiratory difficulty (score 0-3)&#xD;
Respiratory frequency (score 0-3)&#xD;
Presence of apnoea (either 0, or 3)&#xD;
General condition (score 0-3)&#xD;
fever (0-2) The total score is determined by adding each component part. The total score is from 0-20. A score of 0 reflects very mild disease whilst a score of 20 indicates severe disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care costs and resource use</measure>
    <time_frame>3 years</time_frame>
    <description>This will be determined using annual questionnaires sent to participants. The questions include: visits to healthcare providers (hospital, GP), number of admissions and duration where applicable and medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interruption to normal activities associated with RSV disease</measure>
    <time_frame>3 years</time_frame>
    <description>Baseline parental questionnaire followed by 14 day symptom diary at onset of illness. Subsequent annual questionnaire for total of 3 years to determine subsequent disease sequelae.&#xD;
These questionnaires record symptom severity, duration of symptoms, whether the symptoms affect activities of daily living and a record of persisting symptoms. The follow up questionnaires will extract information about subsequent respiratory symptoms (cough, wheeze), whether the participant has required subsequent review by a healthcare practitioner or been admitted to hospital and during of admission. It also records the need for ongoing medications.&#xD;
The information extracted is qualitative in nature. There is no scale used for recording this information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections</measure>
    <time_frame>Year 4</time_frame>
    <description>Parental questionnaires and participant medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections</measure>
    <time_frame>Year 5</time_frame>
    <description>Parental questionnaires and participant medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections</measure>
    <time_frame>Year 6</time_frame>
    <description>Parental questionnaires and participant medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for persistent wheeze at 3 and 6 years of age</measure>
    <time_frame>Year 4</time_frame>
    <description>Demographic and clinical parameters and outcomes from CRF/demographic questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for persistent wheeze at 3 and 6 years of age</measure>
    <time_frame>Year 5</time_frame>
    <description>Demographic and clinical parameters and outcomes from CRF/demographic questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for persistent wheeze at 3 and 6 years of age</measure>
    <time_frame>Year 6</time_frame>
    <description>Demographic and clinical parameters and outcomes from CRF/demographic questionnaires</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>RSV positive ARTI</arm_group_label>
    <description>RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).&#xD;
Group 1 participants are categorised into 4 groups as follows:&#xD;
Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.&#xD;
Group 1c &amp; 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.&#xD;
This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RSV point of care testing</intervention_name>
    <description>Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.</description>
    <arm_group_label>RSV positive ARTI</arm_group_label>
    <other_name>Venepuncture</other_name>
    <other_name>Nasopharyngeal swabs</other_name>
    <other_name>stool sample</other_name>
    <other_name>Urine sample</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants that enrol in Group 1 will have additional consent to retain specimens for the&#xD;
      biobank.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infants less than 12 months old who present to their GP of to hospital with RSV positive&#xD;
        respiratory disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: All of the following must apply&#xD;
&#xD;
          -  parent/carer of the infant is willing and able to give informed consent for&#xD;
             participation in the study&#xD;
&#xD;
          -  Male or female, less than 12 months of age at enrolment&#xD;
&#xD;
          -  Parent has a telephone&#xD;
&#xD;
        For group 1 only:&#xD;
&#xD;
          -  Hospitalised for &lt;48 hours at enrolment or within 96 hours of onset of illness&#xD;
&#xD;
          -  Live near enough to a participating study centre for the 6-8 week home visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants who have received treatment for RSV infection (eg: ribavirin)&#xD;
&#xD;
          -  Infants who have had prior exposure to an RSV vaccine or medication&#xD;
&#xD;
          -  Infants who have received preventative therapy for RSV (eg; palivizumab)&#xD;
&#xD;
          -  Infants who have received oral steroids or montelukast within 7days of enrolment on&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Pollard</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford Vaccine Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://resc-eu.org/</url>
    <description>RESCEU website (coordinators of the Understanding RSV study)</description>
  </link>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised individual participant data sets will be shared with other researchers within the RESCEU consortium. These data sets will include information from participants baseline and annual questionnaires and results from bloods, respiratory samples, urine and stool specimens taken at onset of RSV illness and at 6-8 weeks convalescence.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be shared between researchers within the RESCEU consortium as soon as available during the study period. This is currently ongoing. Sharing of the final study information will occur 12-24 months after completion.</ipd_time_frame>
    <ipd_access_criteria>During the study period only researchers involved within the RESCEU consortium will have access to the anonymised individual participant data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03756766
org study id: OVG 2017/02
nct id: NCT03756766
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The study design is a case-control, sample based study. 275 cases (Group 1), infants <12
      months old with RSV infection and 40 controls (Group 2), otherwise healthy infants <12 months
      old without RSV infection will be recruited. Samples will be taken on enrolment and for
      infants in Group 1; repeated at 7 weeks convalescence. There will be annual follow up by
      questionnaire for up to 6 years and a minimum of 1 year, depending at what stage in the study
      the infant is enrolled.
Human respiratory syncytial virus (RSV) causes severe disease in the very young, elderly and
      in high risk groups. Worldwide in 2005 there were an estimated 34 million cases of acute
      lower respiratory tract infection (ALRI), 3.4 million ALRI hospitalisations and 55,000 to
      199,000 deaths associated with RSV in children <5 years old. RSV infection in childhood is
      associated with subsequent wheezing and asthma. These long-term sequelae pose a substantial
      additional burden on healthcare systems. There is a parallel need to assemble clinical
      resources to identify the correlates of severe RSV disease for clinical management,
      classification of disease severity in clinical trials and identification of biomarkers for
      severe disease, which are currently lacking.

      Group 1: Infants under 12 months with an RSV infection will have nasopharyngeal swabs, blood,
      urine and stool samples taken at the onset of infection and again 6 - 8 weeks later, in
      convalescence. An online diary will be completed for 2 weeks during illness to record the
      participant and parent health. The participant and their family will be followed up annually
      by questionnaire, for a maximum of 6 years. When the study data are analysed, the infants
      will be subdivided into 4 further groups; healthy infants requiring hospitalisation, healthy
      infants not requiring hospitalisation, infants with co-morbidity, requiring hospitalisation
      and infants with a co-morbidity not requiring hospitalisation. Group 2: Well, healthy
      infants, under 12 months with no acute respiratory infection will have nasopharyngeal
      swab,blood, urine and stool samples taken on enrolment. They will receive a follow up contact
      7 days after enrolment to assess if they have developed any illness. The participant and
      their family will be followed up annually by questionnaire, for a maximum of 6 years.
observational model: Case-Control
time perspective: Prospective
measure: Ribonucleic acid (RNA) transcripts (Transcriptomics) that are up and down regulated in severe RSV infection
time frame: 8 weeks
description: Analysis of blood to determine cellular expression of RNA during a severe, acute RSV respiratory tract infection
measure: Cellular protein concentration changes (proteomics) in response to severe RSV infection
time frame: 8 weeks
description: Analysis of blood samples to determine how cellular protein concentrations change in response to severe RSV infection
measure: Cellular metabolite concentration changes associated with severe RSV disease
time frame: 8 weeks
description: Analysis of urine and blood to identify which metabolic pathways are up-regulated at a cellular level following severe RSV infection. This is determined by measuring metabolic by-products
measure: The relationship between infant RSV infection of different severity and school age asthma
time frame: Year 6
description: Symptoms of asthma, diagnosis and use of asthma medication will be measured by parental questionnaire/medical records.
measure: Ribonucleic acid (RNA) transcripts that are up or down regulated and contribute to respiratory sequelae following RSV infection in infants
time frame: 3 years
description: Analysis of blood samples will determine changes in cellular RNA associated with RSV infection.
measure: Cellular protein concentration changes (Proteomics) affecting respiratory sequelae following RSV infection in infants
time frame: 3 years
description: Analysis of blood to determine how cellular protein production is up or down regulated in response to RSV infection to correlate with subsequent respiratory sequelae
measure: Cellular metabolite concentration changes that contribute to respiratory sequelae following RSV infection
time frame: 3 years
description: Analysis of blood and urine to determine which cellular metabolites are produced in increasing quantities during RSV infection and which are subsequently responsible for respiratory sequelae.
measure: Respiratory sequelae following RSV infection in infants
time frame: 3 years
description: Respiratory sequelae in participants will be determined by completion of a baseline questionnaire followed by an annual questionnaire for a maximum of 3 years.
The questionnaires record patient demographics, number of siblings, family history of atopy, exposure to household smoke and pets and the ability of the child and family members to complete their usual activities
measure: Viral load associated with mild and severe RSV disease
time frame: 8 weeks
description: Nasopharyngeal swabs will be taken at baseline and at 6-8weeks to measure viral load
measure: Genetic sequence of RSV associated with mild and severe disease
time frame: 8 weeks
description: Nasopharyngeal samples will be taken at baseline and at 6-8weeks do determine the genetic sequencing of the Respiratory Syncytial Virus.
measure: Cellular immune response during RSV infection
time frame: 8 weeks
description: Whole blood will be used for flow cytometric cell phenotyping to determine which immune cells are activated in response to RSV
measure: Cytokine release associated with severe RSV disease
time frame: 8 weeks
description: Whole blood will be used to perform intracellular cytokine staining in response to RSV infection
measure: Altered gene expression associated with severe RSV disease
time frame: 8 weeks
description: Blood sampling to determine epigenetic changes associated with RSV infection
measure: RSV disease severity
time frame: 8 weeks
description: This is determined using a standardized respiratory clinical severity score (ReSVinet) which is performed at baseline.
This score has 7 subscales;
Feeding intolerance (Score 0-3)
Medical intervention (score 0-3)
Respiratory difficulty (score 0-3)
Respiratory frequency (score 0-3)
Presence of apnoea (either 0, or 3)
General condition (score 0-3)
fever (0-2) The total score is determined by adding each component part. The total score is from 0-20. A score of 0 reflects very mild disease whilst a score of 20 indicates severe disease
measure: Health care costs and resource use
time frame: 3 years
description: This will be determined using annual questionnaires sent to participants. The questions include: visits to healthcare providers (hospital, GP), number of admissions and duration where applicable and medication use.
measure: Interruption to normal activities associated with RSV disease
time frame: 3 years
description: Baseline parental questionnaire followed by 14 day symptom diary at onset of illness. Subsequent annual questionnaire for total of 3 years to determine subsequent disease sequelae.
These questionnaires record symptom severity, duration of symptoms, whether the symptoms affect activities of daily living and a record of persisting symptoms. The follow up questionnaires will extract information about subsequent respiratory symptoms (cough, wheeze), whether the participant has required subsequent review by a healthcare practitioner or been admitted to hospital and during of admission. It also records the need for ongoing medications.
The information extracted is qualitative in nature. There is no scale used for recording this information.
measure: Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections
time frame: Year 4
description: Parental questionnaires and participant medical records
measure: Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections
time frame: Year 5
description: Parental questionnaires and participant medical records
measure: Compare the incidence of asthma after RSV hospitalisation with incidence of asthma following hospitalisation for viral infections
time frame: Year 6
description: Parental questionnaires and participant medical records
measure: Risk factors for persistent wheeze at 3 and 6 years of age
time frame: Year 4
description: Demographic and clinical parameters and outcomes from CRF/demographic questionnaires
measure: Risk factors for persistent wheeze at 3 and 6 years of age
time frame: Year 5
description: Demographic and clinical parameters and outcomes from CRF/demographic questionnaires
measure: Risk factors for persistent wheeze at 3 and 6 years of age
time frame: Year 6
description: Demographic and clinical parameters and outcomes from CRF/demographic questionnaires
arm group label: RSV positive ARTI
description: RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).
Group 1 participants are categorised into 4 groups as follows:
Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.
Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively.
arm group label: Healthy controls
description: This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.
This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only.
intervention type: Diagnostic Test
intervention name: RSV point of care testing
description: Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
arm group label: RSV positive ARTI
other name: Venepuncture
other name: Nasopharyngeal swabs
other name: stool sample
other name: Urine sample
Participants that enrol in Group 1 will have additional consent to retain specimens for the
      biobank.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: N/A
maximum age: 12 Months
healthy volunteers: Accepts Healthy Volunteers
last name: Andrew Pollard
role: Study Chair
affiliation: Oxford Vaccine Group
facility: 
facility: 
country: United Kingdom
url: http://resc-eu.org/
description: RESCEU website (coordinators of the Understanding RSV study)
responsible party type: Sponsor
sharing ipd: Yes
ipd description: Anonymised individual participant data sets will be shared with other researchers within the RESCEU consortium. These data sets will include information from participants baseline and annual questionnaires and results from bloods, respiratory samples, urine and stool specimens taken at onset of RSV illness and at 6-8 weeks convalescence.
ipd info type: Study Protocol
ipd time frame: Data will be shared between researchers within the RESCEU consortium as soon as available during the study period. This is currently ongoing. Sharing of the final study information will occur 12-24 months after completion.
ipd access criteria: During the study period only researchers involved within the RESCEU consortium will have access to the anonymised individual participant data.